Novel antibiotic effective in the treatment of uncomplicated gonorrhea in Phase II trial

Findings published in the New England Journal of Medicine indicate the promise of zoliflodacin, a novel antibiotic that inhibits DNA synthesis, as a well-tolerated and successful treatment for uncomplicated gonorrhoea.

In the study, the team enrolled 179 participants between the ages of 18–55 with uncomplicated urogenital gonorrhea, untreated urogenital gonorrhea or sexual contact with someone with gonorrhea 14 days prior to enrolment. Participants received either 2 or 3 gram doses of oral zoliflodacin or a 500mg dose of injectable ceftriaxone.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment